Evidence map›Paper›PMID 26791866›Full record

ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2017

Assessment of

Mark I Travin, Milena J Henzlova, Berthe L F van Eck-Smit, Diwakar Jain, Ignasi Carrió, Russell D Folks, Ernest V Garcia, Arnold F Jacobson, Hein J Verberne

Registry-linked trialAbstract readComparative StudyEvaluation StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06965621 (An Open-Label, Exploratory, Phase 2 Scintigraphy Study Evaluating 18F mFBG for Imaging Myocardial Sympathetic Innervation in Subjects With Heart Failure and Implantable Cardioverter-Defibrillators), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06965621 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

An Open-Label, Exploratory, Phase 2 Scintigraphy Study Evaluating 18F mFBG for Imaging Myocardial Sympathetic Innervation in Subjects With Heart Failure and Implantable Cardioverter-Defibrillators

TypeinterventionalSponsorInnervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)Ran2025 to 2026Enrolled20ConditionsHeart Failure, Ischemic Cardiomyopathy, ICD PatientsArms18F-metaFluorobenzylguanidine, Rubidium-82
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. The prognostic value ofJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022
    Pooled it
  2. Trial
  3. Review
  4. The Utility of Baseline Characteristics and [Journal of clinical medicine · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. CardiacPharmaceuticals (Basel, Switzerland) · 2022
    Review
  12. Importance of individual patient characteristics when assessing the ability of cardiac adrenergic imaging to guide ICD use.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022
    Article
  13. Prediction of appropriate ICD therapy in patients with ischemic heart failure.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022
    Article
  14. Machine learning-based risk model usingJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022
    Article
  15. Article
  16. How to best appreciate the possible clinical role of cardiacJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021
    Article
  17. Quality and utility of [Annals of nuclear medicine · 2021
    Article
  18. Review
  19. Early therapeutic effects of adaptive servo-ventilation on cardiac sympathetic nervous function in patients with heart failure evaluated using a combination ofJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019
    Article
  20. Iodine-123-metaiodobenzylguanidine cardiac SPECT imaging in the qualification of heart failure patients for ICD implantation.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 3 countries.

Mark I TravinDivision of Nuclear Medicine, Department of Radiology, Montefiore Medical Center, Albert Einstein College of Medicine, 111 East-210th Street, Bronx, NY, 10467-2490, USA. mtravin@attglobal.net.
Milena J HenzlovaMount Sinai Medical Center, New York, NY, USA.
Berthe L F van Eck-SmitDepartment of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Diwakar JainDivision of Cardiology, Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY, USA.
Ignasi CarrióDepartment of Nuclear Medicine, Hospital Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
Russell D FolksDepartment of Radiology, Emory University Hospital, Emory University School of Medicine, Atlanta, GA, USA.
Ernest V GarciaDepartment of Radiology, Emory University Hospital, Emory University School of Medicine, Atlanta, GA, USA.
Arnold F JacobsonDiagram Consulting, Kihei, HI, USA.
Hein J VerberneDepartment of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Academic Medical Center · NLEmory University Hospital · USAlbert Einstein College of Medicine · USGeneral Electric (Spain) · ESMount Sinai Medical Center · USUniversitat Autònoma de Barcelona · ESWestchester Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationale

methods

results471 patients had images adequate for total 17-segment scoring. There were 48 ArEs (10.2%). Neither

conclusionsThe presumption of a monotonic increase in ArE risk with increasing summed

Indexed as

3-IodobenzylguanidineOrganophosphorus CompoundsOrganotechnetium CompoundsArrhythmias, CardiacCausalityComorbidityFemaleHeart FailureHumansIncidenceInternationalityMaleMiddle AgedMyocardial IschemiaPrognosisRadiopharmaceuticals3-IodobenzylguanidineOrganophosphorus CompoundsOrganotechnetium CompoundsRadiopharmaceuticalstechnetium tc-99m tetrofosmin123I-mIBGarrhythmiasheart failureSPECT

Identifiers

PMID26791866
OpenAlexW2265188873

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.